3050 Spruce Street, St. Louis, MO 63103 USA
Tel: (800) 521-8956 (314) 771-5765 Fax: (800) 325-5052 (314) 771-5757
email: techservice@sial.com sigma-aldrich.com

Product Information

MMP-9, pre-activated, human
recombinant, expressed in HEK 293 cells

Catalog Number **SAE0078**
Storage Temperature –20 °C

EC 3.4.24.35
Synonyms: GELB, GELBCLG4B, Gelatinase B, Gelatinase, MANDP2, MMP-9, Matrix Metalloproteinase-10, Type IV collagenase
Uniprot: P14780

Product Description

Matrix Metalloproteinase-9 (MMP-9) is a member of the matrix metalloproteinase (MMP) family of proteins. MMPs participate in the breakdown of extracellular matrix in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis.[1] MMP-9 is secreted from neutrophils, macrophages, and a number of transformed cells. MMP-9 is the most complex family member in terms of domain structure and regulation of its activity.[2]

Structurally, MMP-9 may be divided into five distinct domains:[3,4]

- a pro-domain which is cleaved upon activation
- a gelatin-binding domain consisting of three contiguous fibronectin type II units
- a catalytic domain containing the zinc binding site
- a proline-rich linker region
- a carboxyl terminal hemopexin-like domain

Studies in rhesus monkeys suggest that MMP-9 is involved in interleukin-8 (IL-8)-induced mobilization of hematopoietic progenitor cells from bone marrow, and murine studies suggest a role in tumor-associated tissue remodeling.[2] Thrombospondins, intervertebral disc proteins, regulate the effective levels of MMP-2 and MMP-9, which are key effectors of extracellular matrix (ECM) remodeling.[5]

MMP-9 degrades various substrates, including gelatin, collagen types IV and V, and elastin.[3] MMP-9 is involved in various autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. MMP-9 thus may be regarded as a potential therapeutic target.[6]

As with most MMPs, MMP-9 is secreted as an inactive pro-protein which is activated when cleaved by extracellular proteinases.[1] This product was **pre-activated** *in vitro* using 4-aminophenylmercuric acetate (APMA). Thus, it is active and ready for use. The highly toxic APMA was removed from the final preparation.

This product is expressed in human HEK 293 cells as a glycoprotein with a calculated molecular mass of 76 kDa (amino acids 20-707). The DTT-reduced protein migrates as a ~92 kDa polypeptide on SDS-PAGE because of glycosylation. This protein is produced in human cells, without the use of serum. The human cells expression system allows human-like glycosylation and folding, and often supports higher specific activity of the protein. This recombinant protein is expressed without artificial tags.

This product is supplied as a 0.22 μm-filtered solution, containing 25 mM Trizma®, pH 7.5, containing 10 mM $CaCl_2$, 150 mM NaCl, and 0.05% Brij® 35.

The specific activity of this recombinant human MMP-9 is measured by its ability to cleave the fluorogenic peptide Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH_2 (Mca-PLGL-Dpa-AR-NH_2; Mca = 7-Methoxycoumarin-4-yl)acetyl; Dpa = *N*-3-(2, 4-Dinitrophenyl)-L-2,3-diaminopropionyl).

Specific activity: ≥1,300 pmol/min/μg

Purity: ≥95% (SDS-PAGE)

(The related product SAE0077, MMP-9 human recombinant ≥1,300 pmol/min/μg, expressed in HEK 293 cells), is **not** activated with APMA.)

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability
Store the product at –20 °C. The product retains its activity for at least 2 years as supplied. After initial thawing, it is recommended to store the protein in working aliquots at –20 °C.

References

1. Vos, M.C. *et al.*, *Reprod. Biol. Endocrinol.*, **12**, 12 (2014).
2. Pruijt, J.F. *et al.*, *Proc. Nat. Acad. Sci. USA*, **96(19)**, 10863-10868 (1999).
3. Somerville, R.P. *et al.*, *Genome Biol.*, **4(6)**, 216-216 (2003).
4. Tallant, C. *et al.*, *Biochim. Biophys. Acta*, **1803(1)**, 20-28 (2010).
5. Rodriguez-Manzaneque, J.C. *et al.*, *Proc. Nat. Acad. Sci. USA*, **98(22)**, 12485-12490 (2001).
6. Chang, Y.H. *et al.*, *Clin. Biochem.*, **41(12)**, 955-959 (2008).

NA,LB,GCY,MAM 01/18-1